ClinicalTrials.gg
RecruitingNCT04951622Updated Nov 5, 2026Results posted

A Study of Nipocalimab Administered to Adults With Generalized Myasthenia Gravis

A Phase 3 interventional study of Nipocalimab and Placebo in Myasthenia Gravis, sponsored by Janssen Research & Development, LLC. Recruiting at 112 sites in 17 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-05.

Sponsored by Janssen Research & Development, LLC (part of Johnson & Johnson) · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Started Jul 2021; still recruiting 5 years 4 months later.
Updated Nov 5, 2026Eligibility revised1 site added+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
199
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 144 studies in Myasthenia Gravis with a site in United States — 53 open to participants now, 73 under way, 25 of them phase 3. Myasthenia Gravis · United States.

Planned enrollment
9th of 108
199 · median 56
Started
2021
with 12 others
Phase 3
45 of 144
9 open now
Primary completion
2023-11
later than 1 of 72 live
Registered
65th of 144
by date
Lead sponsor
3 of 144
Janssen Research & Development, LLC

Among the 144 studies in Myasthenia Gravis with a site in United States, this one is the 9th largest by planned enrollment of the 108 interventional ones that give a count, is one of 13 that started in 2021, is one of 45 in phase 3, reaches primary completion later than 1 of the 72 other live ones, and was the 65th registered.

Myasthenia Gravis

331 studies on the registry are indexed under Myasthenia Gravis; 145 are open to participants now.

Browse Myasthenia Gravis studies →

Open to participants now

53 of the 144 studies in Myasthenia Gravis with a site in United States are open now. Recruiting first, the newest first:

48 more — sign in →

All 53 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 104 Myasthenia Gravis studies recruiting now, 64 (62%) set no upper age limit and 23 (22%) stop at 75 or younger; 16 take children under 18; 13 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 144 studies in Myasthenia Gravis with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the efficacy and safety of nipocalimab compared to placebo in participants with generalized myasthenia gravis (gMG). The purpose of the subcutaneous substudy is to evaluate how well it works in the body (pharmacodynamic [PD]) when given as an injection under the skin (subcutaneous) compared to when given through a vein (intravenous) in participants with gMG.

03

Conditions studied

  • Myasthenia Gravis

Browse trials for

04

Who can participate

The criteria were revised on the registry on Nov 5, 2026. See what changed

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of myasthenia gravis (MG) with generalized muscle weakness meeting the clinical criteria for generalized myasthenia gravis (gMG) as defined by the Myasthenia Gravis Foundation of America (MGFA) Clinical Classification Class II a/b, III a/b, or IVa/b at screening
  • Myasthenia Gravis - Activities of Daily Living (MG-ADL) score of greater than or equal to (>=) 6 at screening and baseline
  • Has sufficient venous access to allow drug administration by infusion and blood sampling as per the protocol
  • A woman of must have a negative highly sensitive serum (beta-human chorionic gonadotropin [beta-hCG]) at screening and a negative urine pregnancy test at Day 1 prior to administration of study intervention
  • A male participant must agree not to donate sperm for the purpose of reproduction during the study and for a minimum 90 days after receiving the last administration of study intervention
  • For the SC Substudy (Cohort 1 and Cohort 2): Has reasonable abdominal skin area for SC administration
  • For the SC Substudy (Cohort 1 and Cohort 2): Participants must be willing to comply with maintaining their stable dose of and/or for the initial 8 weeks of the SC substudy, that is, through the SC Week 8 visit

Exclusion criteria

Exclusion Criteria:

  • Has any confirmed or suspected clinical immunodeficiency syndrome not related to treatment of his/her gMG, or has a family history of congenital or hereditary immunodeficiency unless confirmed absent in the participant
  • Has MGFA Class I disease or presence of MG crisis (MGFA Class V) at screening, history of MG crisis within 1 month of screening, or fixed weakness (and/or 'burnt out' MG)
  • Has had a thymectomy within 12 months prior to screening, or thymectomy is planned during the study
  • Has known allergies, , or intolerance to nipocalimab or its
  • Has experienced myocardial infarction, unstable ischemic heart disease, or stroke within 12 weeks of screening
  • For the SC Substudy (Cohort 1): Participants who have undergone a recent tapering of their concomitant MG medication in the OLE. Reminder that increasing the dose of existing MG therapy or starting new MG therapy anytime throughout study conduct is prohibited.
  • For the SC Substudy (Cohort 1): Participants deteriorating during the OLE in the month prior to SC Dose 1 of the SC substudy such that they meet the criteria for clinical deterioration
  • For the SC Substudy (Cohort 2): History of an unprovoked pulmonary embolism within 1 year prior to screening or history of recurrent deep vein thrombosis (DVT)
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
199 participants (estimated)

Study arms

  • Experimental
    Nipocalimab

    Double-blind Placebo-controlled Phase: Participants will receive nipocalimab intravenous (IV) infusions once every 2 weeks (q2w) up to 24 weeks during double-blind placebo-controlled phase. Open-label Extension (OLE) Phase: Participants who complete the double-blind placebo-controlled phase will enter the OLE phase and will have the option to continue to receive nipocalimab q2w IV infusion till study end or enter the nipocalimab SC substudy.

    Drug: Nipocalimab

  • Placebo comparator
    Placebo

    Double-blind Placebo-controlled Phase: Participants will receive matching placebo of nipocalimab IV infusion q2w up to 24 weeks during double-blind placebo-controlled phase.

    Drug: Placebo

  • Experimental
    Nipocalimab Subcutaneous (SC)

    OLE Phase: Participants from Cohort 1 will receive nipocalimab subcutaneous liquid in vial (SC-LIV) qw until Week 8. Participants with gMG from Cohort 2 who have not received nipocalimab previously, will receive nipocalimab SC-LIV until Week 8. Participants who complete the 8-week treatment period will have the opportunity to continue receiving nipocalimab SC-LIV qw in the Long term extension (LTE) period.

    Drug: Nipocalimab SC-LIV

Interventions

  • Nipocalimab will be administered as an IV infusion.

    Also known as: JNJ-80202135, M281

  • DrugPlacebo

    Matching placebo will be administered as an IV infusion.

  • DrugNipocalimab SC-LIV

    Nipocalimab will be administered subcutaneously.

06

What researchers measure

Primary outcomes

  1. Double-blind (DB) Phase: Average Change From Baseline in Myasthenia Gravis - Activities of Daily Living (MG-ADL) Total Score Over Weeks 22, 23, and 24

    Average change from baseline over multiple timepoints (Weeks 22, 23, and 24) was reported in this outcome measure. The MG-ADL provided a rapid assessment of the participant's MG symptom severity of eight functions (talking, chewing, swallowing, breathing, impairment of ability to brush teeth or comb hair, impairment of ability to arise from a chair, double vision, eyelid droop) rated on a 4-point scale ranging from 0 (normal) to 3 (severe). MG-ADL total score was sum of 8 individual items, which ranging from 0 to 24. A higher score indicated greater symptom severity. Baseline was defined as the average of the screening and Day 1 total scores.

    Time frame: Baseline, Weeks 22, 23, and 24

  2. Sub Study: Percent Change in Anti-AChR Autoantibody Titer From Pre-first Nipocalimab Dose on Day 1 up to Week 8 (Day 57)

    Time frame: From pre-first nipocalimab dose on Day 1 up to Week 8 (Day 57)

  3. Sub Study: Percent Change in Total IgG Levels From Pre-first Nipocalimab Dose on Day 1 up to Week 8 (Day 57)

    Time frame: From pre-first nipocalimab dose on Day 1 up to Week 8 (Day 57)

Secondary outcomes

  1. DB Phase: Average Change From Baseline in Quantitative Myasthenia Gravis (QMG) Score Over Weeks 22 and 24

    Time frame: Baseline, Weeks 22, and 24

  2. DB Phase: Percentage of Participants Who Had Achieved at Least a 2-point Average Improvement From Baseline in Myasthenia Gravis - Activities of Daily Living (MG-ADL) Total Score Over Weeks 22, 23, and 24

    Time frame: Weeks 22, 23, and 24

  3. DB Phase: Percentage of Participants Who Had Achieved an Improvement of Greater Than or Equal to (>=) 2 Points in the Myasthenia Gravis - Activities of Daily Living (MG-ADL) Total Score at Week 1 and/or Week 2

    Time frame: Weeks 1 and 2

  4. DB Phase: Percentage of Participants Who Had an Improvement of >= 2 Points in the MG-ADL Total Score From Week 4 Through Week 24 With no More Than 2 Non-consecutive Excursions Allowed Between Weeks 6 Through 23

    Time frame: From Week 4 up to Week 24

  5. DB Phase: Percentage of Participants Who Had Achieved at Least a 50 Percent (%) Average Improvement From Baseline in the Myasthenia Gravis - Activities of Daily Living (MG-ADL) Total Score Over Weeks 22, 23, and 24

    Time frame: Weeks 22, 23, and 24

  6. Percentage of Participants With Treatment-emergent Adverse Events (TEAEs)

    Time frame: From start of treatment (DB phase Day 1) up to 4 years 9 months

  7. Percentage of Participants With Treatment-emergent Serious Adverse Events (TESAEs)

    Time frame: From start of treatment (DB phase Day 1) up to 4 years 9 months

  8. Percentage of Participants With AEs of Special Interest (AESIs)

    Time frame: From start of treatment (DB phase Day 1) up to 4 years 9 months

  9. Number of Participants With Change in Vital Signs

    Time frame: From start of treatment (DB phase Day 1) up to 4 years 9 months

  10. Number of Participants With Change in Clinical Laboratory Values

    Time frame: From start of treatment (DB phase Day 1) up to 4 years 9 months

  11. Number of Participants With Change From Baseline in Columbia-Suicide Severity Rating Scale (C-SSRS) Score

    Time frame: From start of treatment (Day 1) up to 4 years 9 months

  12. DB Phase: Percentage of Participants Who Had an Improvement of >= 3 Points in Quantitative Myasthenia Gravis (QMG) Score From Baseline, at Week 2 Through Week 24, With No More Than 2 Non-consecutive Excursions Allowed Between at Weeks 4 Through Week 22

    Time frame: Baseline, Week 2 up to Week 24

  13. DB Phase: Average Change From Baseline in the Fatigue Items of the Quality of Life in Neurological Disorders (Neuro-QoL) Fatigue Scale Total Score Over Weeks 22 and 24

    Time frame: Baseline up to Weeks 22, and 24

  14. DB Phase: Average Change From Baseline in the Revised Myasthenia Gravis Quality of Life (Revised) Instrument (MG-Qol15r) Score Over Weeks 22 And 24

    Time frame: Baseline up to Weeks 22, and 24

  15. DB Phase: Change From Baseline in the Visual Analog Scale (VAS) Score of European Quality of Life (EuroQol) 5-Dimension 5-Level (EQ-5D-5L) Scale Over 24 Weeks

    Time frame: Baseline up to Week 24

  16. DB Phase: Change From Baseline in the Health Status Index of the EuroQol 5-Dimension 5-Level (EQ-5D-5L) Scale Over 24 Weeks

    Time frame: Baseline up to Week 24

  17. DB Phase: Percentage of Participants With Myasthenia Gravis - Activities of Daily Living (MG-ADL) Score of 0 or 1 Over Time

    Time frame: Baseline up to Week 24

  18. DB Phase: Percentage of Participants With Myasthenia Gravis - Activities of Daily Living (MG-ADL) Score of 0 or 1 at Any Time

    Time frame: Baseline up to Week 24

  19. DB Phase: Percentage of Participants With Myasthenia Gravis - Activities of Daily Living (MG-ADL) Score of 0 or 1 at 50% of Timepoints

    Time frame: Baseline up to Week 24

  20. DB Phase: Percentage of Participants With Myasthenia Gravis - Activities of Daily Living (MG-ADL) Score of 0 or 1 at 75% of Timepoints

    Time frame: Baseline up to Week 24

  21. Serum Concentrations of Nipocalimab Over Time

    Time frame: DB Phase: Predose and 45 minutes post-dose on Day 1, Weeks 2, 4, 8, 12,16, 20, 24;OL Phase: Predose on Day 1, Weeks 8, 16, 24, 36, 48, 60, 72, 84, and 96

  22. Number of Participants With Antibodies to Nipocalimab (Anti-Drug Antibodies [ADAs] and Neutralizing Antibodies [NAbs])

    Time frame: From start of treatment (Day 1) up to 4 years 9 months

  23. Percent Change From Baseline in Total Serum Immunoglobulin G (IgG) Concentrations

    Time frame: Baseline up to 4 years 9 months

  24. Change From Baseline in Levels of Autoantibodies Associated With Generalized Myasthenia Gravis (gMG)

    Time frame: Baseline up to 4 years 9 months

  25. Change From Baseline in Myasthenia Gravis - Activities of Daily Living (MG-ADL) Score as a Function of IgG

    Time frame: Baseline up to 4 years 9 months

  26. Change From Baseline in Quantitative Myasthenia Gravis (QMG) Score as a Function of Immunoglobulin G (IgG)

    Time frame: Baseline up to 4 years 9 months

  27. Change From Baseline in Myasthenia Gravis - Activities of Daily Living (MG-ADL) Score as a Response to Percent Change in Autoantibody Levels in Seropositive Participants Treated With Nipocalimab

    Time frame: Baseline up to 4 years 9 months

  28. Change From Baseline in QMG Score as a Response to Percent Change in Autoantibody Levels in Seropositive Participants Treated With Nipocalimab

    Time frame: Baseline up to 4 years 9 months

  29. Sub Study: Number of Participants With Treatment-Emergent AEs

    Time frame: Up to SC Week 8 (Day 57)

  30. Sub Study: Number of Participants With Abnormalities in Vital Signs

    Time frame: Up to SC Week 8 (Day 57)

  31. Sub Study: Number of Participants With Abnormalities in Physical Examinations

    Time frame: Up to SC Week 8 (Day 57)

  32. Sub Study: Number of Participants With Abnormalities in Laboratory Parameters

    Time frame: Up to SC Week 8 (Day 57)

  33. Sub Study: Numeric Pain Rating Scale (NPRS) Assessment With SC Use of Nipocalimab

    Time frame: Up to SC Week 8 (Day 57)

  34. Sub Study: Number of Participants With Injection Site-Reactions

    Time frame: Up to SC Week 8 (Day 57)

  35. Sub Study: Change From Baseline in MG-ADL Clinician-Reported Outcome Measures up to Week 8 (Day 57)

    Time frame: From baseline (pre-first nipocalimab dose on Day 1) up to Week 8 (Day 57)

  36. Sub Study: Change From Baseline in QMG Clinician-Reported Outcome Measures up to Week 8 (Day 57)

    Time frame: From baseline (pre-first nipocalimab dose on Day 1) up to Week 8 (Day 57)

  37. Sub Study: Change From Baseline in Myasthenia Gravis Foundation of America (MGFA) Clinician-Reported Measures up to Week 8 (Day 57)

    Time frame: From baseline (pre-first nipocalimab dose on Day 1) up to Week 8 (Day 57)

  38. Sub Study: Change From Baseline in C-SSRS Clinician-Reported Outcome Measures up to Week 8 (Day 57)

    Time frame: From baseline (pre-first nipocalimab dose on Day 1) up to Week 8 (Day 57)

  39. Sub Study: Change From Baseline in Neuro-QoL Participant-Reported Outcome Measures up to Week 8 (Day 57)

    Time frame: From baseline (pre-first nipocalimab dose on Day 1) up to Week 8 (Day 57)

  40. Sub Study: Change From Baseline in Patient Global Impression of Severity (PGIS) Scale Score up to Week 8 (Day 57)

    Time frame: From baseline (pre-first nipocalimab dose on Day 1) up to Week 8 (Day 57)

  41. Sub Study: Change From Baseline in Patient Global Impression of Change (PGIC) Scale Score up to Week 8 (Day 57)

    Time frame: From baseline (pre-first nipocalimab dose on Day 1) up to Week 8 (Day 57)

  42. Sub Study: Change From Baseline in MG-QoL Participant-Reported Outcome Measures up to Week 8 (Day 57)

    Time frame: From baseline (pre-first nipocalimab dose on Day 1) up to Week 8 (Day 57)

  43. Sub Study: Change From Baseline in EQ-5D-5L Participant-Reported Outcome Measures up to Week 8 (Day 57)

    Time frame: From baseline (pre-first nipocalimab dose on Day 1) up to Week 8 (Day 57)

  44. Sub Study: Percent Change in Total IgG Levels From Pre-first Nipocalimab Dose on Day 1 up to Week 8 (Day 57)

    Time frame: From pre-first nipocalimab dose on Day 1 up to Week 8 (Day 57)

  45. Sub Study: Percent Change in Anti-AChR Autoantibody Titer From Pre-first Nipocalimab Dose on Day 1 up to Week 8 (Day 57)

    Time frame: From pre-first nipocalimab dose on Day 1 up to Week 8 (Day 57)

07

Results

Posted Jul 23, 2025

Participant flow

DB Phase: Day 1 (Week 0) to Week 24
Participant flow — DB Phase: Day 1 (Week 0) to Week 24
MilestoneDouble Blind (DB) Phase: PlaceboDB Phase: NipocalimabOLE Phase: Placebo to NipocalimabOLE Phase: NipocalimabOLE Phase: Nipocalimab (MOM-M281-004 and MOM-M281-005)
Started99100000
Treated9898000
Completed8287000
Not completed1713000
Withdrew: Adverse event75000
Withdrew: Protocol violation22000
Withdrew: Death21000
Withdrew: Disease relapse01000
Withdrew: Progressive disease11000
Withdrew: Withdrawal by subject01000
Withdrew: Lack of efficacy20000
Withdrew: Randomized by mistake10000
Withdrew: Subject refused further study treatment10000
Withdrew: Other01000
Withdrew: Pregnancy10000
Withdrew: Failure to meet randomization criteria01000
OLE: Week 24 (OLE Day 1) up to 2 Years
Participant flow — OLE: Week 24 (OLE Day 1) up to 2 Years
MilestoneDouble Blind (DB) Phase: PlaceboDB Phase: NipocalimabOLE Phase: Placebo to NipocalimabOLE Phase: NipocalimabOLE Phase: Nipocalimab (MOM-M281-004 and MOM-M281-005)
Started00888820
Treated00888819
Completed00000
Not completed00888820
Withdrew: Adverse event00502
Withdrew: Death00011
Withdrew: Withdrawal by subject00151
Withdrew: Lack of efficacy00370
Withdrew: Lost to follow-up00100
Withdrew: Physician decision00110
Withdrew: Ongoing00777415
Withdrew: Met eligibility criteria but discontinued during the screening period (not treated)00001

Outcome measures

PrimaryDouble-blind (DB) Phase: Average Change From Baseline in Myasthenia Gravis - Activities of Daily Living (MG-ADL) Total Score Over Weeks 22, 23, and 24

Average change from baseline over multiple timepoints (Weeks 22, 23, and 24) was reported in this outcome measure. The MG-ADL provided a rapid assessment of the participant's MG symptom severity of eight functions (talking, chewing, swallowing, breathing, impairment of ability to brush teeth or comb hair, impairment of ability to arise from a chair, double vision, eyelid droop) rated on a 4-point scale ranging from 0 (normal) to 3 (severe). MG-ADL total score was sum of 8 individual items, which ranging from 0 to 24. A higher score indicated greater symptom severity. Baseline was defined as the average of the screening and Day 1 total scores.

Time frame:
Baseline, Weeks 22, 23, and 24
Reported as:
Least squares mean · Score on a scale
Double-blind (DB) Phase: Average Change From Baseline in Myasthenia Gravis - Activities of Daily Living (MG-ADL) Total Score Over Weeks 22, 23, and 24
Score on a scaleDouble Blind (DB) Phase: PlaceboDB Phase: Nipocalimab
Double-blind (DB) Phase: Average Change From Baseline in Myasthenia Gravis - Activities of Daily Living (MG-ADL) Total Score Over Weeks 22, 23, and 24-3.25 ± 0.335-4.70 ± 0.329
Statistical analysis
  • Double Blind (DB) Phase: Placebo vs DB Phase: Nipocalimab · mixed effects model for repeated measure · p = =0.002 · Difference of ls means: -1.45 · 95% CI -2.38 to -0.52
SecondaryDB Phase: Average Change From Baseline in Quantitative Myasthenia Gravis (QMG) Score Over Weeks 22 and 24
Time frame:
Baseline, Weeks 22, and 24

Results for this outcome have not been posted.

SecondaryDB Phase: Percentage of Participants Who Had Achieved at Least a 2-point Average Improvement From Baseline in Myasthenia Gravis - Activities of Daily Living (MG-ADL) Total Score Over Weeks 22, 23, and 24
Time frame:
Weeks 22, 23, and 24

Results for this outcome have not been posted.

SecondaryDB Phase: Percentage of Participants Who Had Achieved an Improvement of Greater Than or Equal to (>=) 2 Points in the Myasthenia Gravis - Activities of Daily Living (MG-ADL) Total Score at Week 1 and/or Week 2
Time frame:
Weeks 1 and 2

Results for this outcome have not been posted.

SecondaryDB Phase: Percentage of Participants Who Had an Improvement of >= 2 Points in the MG-ADL Total Score From Week 4 Through Week 24 With no More Than 2 Non-consecutive Excursions Allowed Between Weeks 6 Through 23
Time frame:
From Week 4 up to Week 24

Results for this outcome have not been posted.

SecondaryDB Phase: Percentage of Participants Who Had Achieved at Least a 50 Percent (%) Average Improvement From Baseline in the Myasthenia Gravis - Activities of Daily Living (MG-ADL) Total Score Over Weeks 22, 23, and 24
Time frame:
Weeks 22, 23, and 24

Results for this outcome have not been posted.

SecondaryPercentage of Participants With Treatment-emergent Adverse Events (TEAEs)
Time frame:
From start of treatment (DB phase Day 1) up to 4 years 9 months

Results for this outcome have not been posted.

SecondaryPercentage of Participants With Treatment-emergent Serious Adverse Events (TESAEs)
Time frame:
From start of treatment (DB phase Day 1) up to 4 years 9 months

Results for this outcome have not been posted.

SecondaryPercentage of Participants With AEs of Special Interest (AESIs)
Time frame:
From start of treatment (DB phase Day 1) up to 4 years 9 months

Results for this outcome have not been posted.

SecondaryNumber of Participants With Change in Vital Signs
Time frame:
From start of treatment (DB phase Day 1) up to 4 years 9 months

Results for this outcome have not been posted.

SecondaryNumber of Participants With Change in Clinical Laboratory Values
Time frame:
From start of treatment (DB phase Day 1) up to 4 years 9 months

Results for this outcome have not been posted.

SecondaryNumber of Participants With Change From Baseline in Columbia-Suicide Severity Rating Scale (C-SSRS) Score
Time frame:
From start of treatment (Day 1) up to 4 years 9 months

Results for this outcome have not been posted.

SecondaryDB Phase: Percentage of Participants Who Had an Improvement of >= 3 Points in Quantitative Myasthenia Gravis (QMG) Score From Baseline, at Week 2 Through Week 24, With No More Than 2 Non-consecutive Excursions Allowed Between at Weeks 4 Through Week 22
Time frame:
Baseline, Week 2 up to Week 24

Results for this outcome have not been posted.

SecondaryDB Phase: Average Change From Baseline in the Fatigue Items of the Quality of Life in Neurological Disorders (Neuro-QoL) Fatigue Scale Total Score Over Weeks 22 and 24
Time frame:
Baseline up to Weeks 22, and 24

Results for this outcome have not been posted.

SecondaryDB Phase: Average Change From Baseline in the Revised Myasthenia Gravis Quality of Life (Revised) Instrument (MG-Qol15r) Score Over Weeks 22 And 24
Time frame:
Baseline up to Weeks 22, and 24

Results for this outcome have not been posted.

SecondaryDB Phase: Change From Baseline in the Visual Analog Scale (VAS) Score of European Quality of Life (EuroQol) 5-Dimension 5-Level (EQ-5D-5L) Scale Over 24 Weeks
Time frame:
Baseline up to Week 24

Results for this outcome have not been posted.

SecondaryDB Phase: Change From Baseline in the Health Status Index of the EuroQol 5-Dimension 5-Level (EQ-5D-5L) Scale Over 24 Weeks
Time frame:
Baseline up to Week 24

Results for this outcome have not been posted.

SecondaryDB Phase: Percentage of Participants With Myasthenia Gravis - Activities of Daily Living (MG-ADL) Score of 0 or 1 Over Time
Time frame:
Baseline up to Week 24

Results for this outcome have not been posted.

SecondaryDB Phase: Percentage of Participants With Myasthenia Gravis - Activities of Daily Living (MG-ADL) Score of 0 or 1 at Any Time
Time frame:
Baseline up to Week 24

Results for this outcome have not been posted.

SecondaryDB Phase: Percentage of Participants With Myasthenia Gravis - Activities of Daily Living (MG-ADL) Score of 0 or 1 at 50% of Timepoints
Time frame:
Baseline up to Week 24

Results for this outcome have not been posted.

SecondaryDB Phase: Percentage of Participants With Myasthenia Gravis - Activities of Daily Living (MG-ADL) Score of 0 or 1 at 75% of Timepoints
Time frame:
Baseline up to Week 24

Results for this outcome have not been posted.

SecondarySerum Concentrations of Nipocalimab Over Time
Time frame:
DB Phase: Predose and 45 minutes post-dose on Day 1, Weeks 2, 4, 8, 12,16, 20, 24;OL Phase: Predose on Day 1, Weeks 8, 16, 24, 36, 48, 60, 72, 84, and 96

Results for this outcome have not been posted.

SecondaryNumber of Participants With Antibodies to Nipocalimab (Anti-Drug Antibodies [ADAs] and Neutralizing Antibodies [NAbs])
Time frame:
From start of treatment (Day 1) up to 4 years 9 months

Results for this outcome have not been posted.

SecondaryPercent Change From Baseline in Total Serum Immunoglobulin G (IgG) Concentrations
Time frame:
Baseline up to 4 years 9 months

Results for this outcome have not been posted.

SecondaryChange From Baseline in Levels of Autoantibodies Associated With Generalized Myasthenia Gravis (gMG)
Time frame:
Baseline up to 4 years 9 months

Results for this outcome have not been posted.

SecondaryChange From Baseline in Myasthenia Gravis - Activities of Daily Living (MG-ADL) Score as a Function of IgG
Time frame:
Baseline up to 4 years 9 months

Results for this outcome have not been posted.

SecondaryChange From Baseline in Quantitative Myasthenia Gravis (QMG) Score as a Function of Immunoglobulin G (IgG)
Time frame:
Baseline up to 4 years 9 months

Results for this outcome have not been posted.

SecondaryChange From Baseline in Myasthenia Gravis - Activities of Daily Living (MG-ADL) Score as a Response to Percent Change in Autoantibody Levels in Seropositive Participants Treated With Nipocalimab
Time frame:
Baseline up to 4 years 9 months

Results for this outcome have not been posted.

SecondaryChange From Baseline in QMG Score as a Response to Percent Change in Autoantibody Levels in Seropositive Participants Treated With Nipocalimab
Time frame:
Baseline up to 4 years 9 months

Results for this outcome have not been posted.

PrimarySub Study: Percent Change in Anti-AChR Autoantibody Titer From Pre-first Nipocalimab Dose on Day 1 up to Week 8 (Day 57)
Time frame:
From pre-first nipocalimab dose on Day 1 up to Week 8 (Day 57)

Results for this outcome have not been posted.

PrimarySub Study: Percent Change in Total IgG Levels From Pre-first Nipocalimab Dose on Day 1 up to Week 8 (Day 57)
Time frame:
From pre-first nipocalimab dose on Day 1 up to Week 8 (Day 57)

Results for this outcome have not been posted.

SecondarySub Study: Number of Participants With Treatment-Emergent AEs
Time frame:
Up to SC Week 8 (Day 57)

Results for this outcome have not been posted.

SecondarySub Study: Number of Participants With Abnormalities in Vital Signs
Time frame:
Up to SC Week 8 (Day 57)

Results for this outcome have not been posted.

SecondarySub Study: Number of Participants With Abnormalities in Physical Examinations
Time frame:
Up to SC Week 8 (Day 57)

Results for this outcome have not been posted.

SecondarySub Study: Number of Participants With Abnormalities in Laboratory Parameters
Time frame:
Up to SC Week 8 (Day 57)

Results for this outcome have not been posted.

SecondarySub Study: Numeric Pain Rating Scale (NPRS) Assessment With SC Use of Nipocalimab
Time frame:
Up to SC Week 8 (Day 57)

Results for this outcome have not been posted.

SecondarySub Study: Number of Participants With Injection Site-Reactions
Time frame:
Up to SC Week 8 (Day 57)

Results for this outcome have not been posted.

SecondarySub Study: Change From Baseline in MG-ADL Clinician-Reported Outcome Measures up to Week 8 (Day 57)
Time frame:
From baseline (pre-first nipocalimab dose on Day 1) up to Week 8 (Day 57)

Results for this outcome have not been posted.

SecondarySub Study: Change From Baseline in QMG Clinician-Reported Outcome Measures up to Week 8 (Day 57)
Time frame:
From baseline (pre-first nipocalimab dose on Day 1) up to Week 8 (Day 57)

Results for this outcome have not been posted.

SecondarySub Study: Change From Baseline in Myasthenia Gravis Foundation of America (MGFA) Clinician-Reported Measures up to Week 8 (Day 57)
Time frame:
From baseline (pre-first nipocalimab dose on Day 1) up to Week 8 (Day 57)

Results for this outcome have not been posted.

SecondarySub Study: Change From Baseline in C-SSRS Clinician-Reported Outcome Measures up to Week 8 (Day 57)
Time frame:
From baseline (pre-first nipocalimab dose on Day 1) up to Week 8 (Day 57)

Results for this outcome have not been posted.

SecondarySub Study: Change From Baseline in Neuro-QoL Participant-Reported Outcome Measures up to Week 8 (Day 57)
Time frame:
From baseline (pre-first nipocalimab dose on Day 1) up to Week 8 (Day 57)

Results for this outcome have not been posted.

SecondarySub Study: Change From Baseline in Patient Global Impression of Severity (PGIS) Scale Score up to Week 8 (Day 57)
Time frame:
From baseline (pre-first nipocalimab dose on Day 1) up to Week 8 (Day 57)

Results for this outcome have not been posted.

SecondarySub Study: Change From Baseline in Patient Global Impression of Change (PGIC) Scale Score up to Week 8 (Day 57)
Time frame:
From baseline (pre-first nipocalimab dose on Day 1) up to Week 8 (Day 57)

Results for this outcome have not been posted.

SecondarySub Study: Change From Baseline in MG-QoL Participant-Reported Outcome Measures up to Week 8 (Day 57)
Time frame:
From baseline (pre-first nipocalimab dose on Day 1) up to Week 8 (Day 57)

Results for this outcome have not been posted.

SecondarySub Study: Change From Baseline in EQ-5D-5L Participant-Reported Outcome Measures up to Week 8 (Day 57)
Time frame:
From baseline (pre-first nipocalimab dose on Day 1) up to Week 8 (Day 57)

Results for this outcome have not been posted.

SecondarySub Study: Percent Change in Total IgG Levels From Pre-first Nipocalimab Dose on Day 1 up to Week 8 (Day 57)
Time frame:
From pre-first nipocalimab dose on Day 1 up to Week 8 (Day 57)

Results for this outcome have not been posted.

SecondarySub Study: Percent Change in Anti-AChR Autoantibody Titer From Pre-first Nipocalimab Dose on Day 1 up to Week 8 (Day 57)
Time frame:
From pre-first nipocalimab dose on Day 1 up to Week 8 (Day 57)

Results for this outcome have not been posted.

Adverse events

Collected over DB: All-cause mortality: From screening (Day -28) to Week 24; SAE and other AEs: From Day 1 (Week 0) to Week 24; OLE: From Week 24 (OLE Day 1) up to 2 years. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Double Blind (DB) Phase: Placebo2/99 (2%)14/98 (14.3%)65/98 (66.3%)
DB Phase: Nipocalimab1/100 (1%)9/98 (9.2%)69/98 (70.4%)
OLE Phase: Placebo to Nipocalimab1/88 (1.1%)10/88 (11.4%)57/88 (64.8%)
OLE Phase: Nipocalimab1/88 (1.1%)16/88 (18.2%)59/88 (67%)
OLE Phase: Nipocalimab (MOMM281- 004 and MOM-M281-005)1/19 (5.3%)7/19 (36.8%)18/19 (94.7%)
Most frequent serious events
Showing 10 of 63
Most frequent serious events
EventDouble Blind (DB) Phase: PlaceboDB Phase: NipocalimabOLE Phase: Placebo to NipocalimabOLE Phase: NipocalimabOLE Phase: Nipocalimab (MOMM281- 004 and MOM-M281-005)
Myasthenia GravisNervous system disorders4/983/981/886/882/19
Atrial FibrillationCardiac disorders0/980/980/880/881/19
Cardio-Respiratory ArrestCardiac disorders0/980/980/880/881/19
Escherichia BacteraemiaInfections and infestations0/980/980/880/881/19
SepsisInfections and infestations1/980/981/881/881/19
Urinary Tract InfectionInfections and infestations0/980/980/880/881/19
Hip FractureInjury, poisoning and procedural complications0/980/980/880/881/19
Spinal FractureInjury, poisoning and procedural complications0/980/980/880/881/19
Myasthenia Gravis CrisisNervous system disorders2/981/981/880/881/19
Major DepressionPsychiatric disorders0/980/980/880/881/19
Most frequent other events
Showing 10 of 131
Most frequent other events
EventDouble Blind (DB) Phase: PlaceboDB Phase: NipocalimabOLE Phase: Placebo to NipocalimabOLE Phase: NipocalimabOLE Phase: Nipocalimab (MOMM281- 004 and MOM-M281-005)
Covid-19Infections and infestations9/9811/987/887/885/19
Upper Respiratory Tract InfectionInfections and infestations8/986/989/889/885/19
Pain in ExtremityMusculoskeletal and connective tissue disorders3/985/982/884/884/19
Myasthenia GravisNervous system disorders9/989/985/888/884/19
HeadacheNervous system disorders17/9814/9810/885/882/19
DiarrhoeaGastrointestinal disorders3/987/985/882/883/19
BronchitisInfections and infestations1/982/982/882/883/19
FallInjury, poisoning and procedural complications1/980/983/882/883/19
NasopharyngitisInfections and infestations10/989/9811/8810/882/19
Muscle SpasmsMusculoskeletal and connective tissue disorders3/9812/983/886/882/19

Baseline characteristics

The full analysis set included all randomized participants who received at least 1 dose (partial or complete) of any study intervention in the double-blind phase. The safety analysis set (OL) included all participants who received at least 1 dose (partial or complete) of nipocalimab in the OLE phase

Age, Continuous
Age, Continuous(Years)Double Blind (DB) Phase: PlaceboDB Phase: NipocalimabOLE Phase: Nipocalimab (MOM-M281-004 and MOM-M281-005)Total
Mean52.7 ± 15.6052.9 ± 15.4952.7 ± 17.6952.8 ± 15.74
Sex: Female, Male
Sex: Female, Male(Participants)Double Blind (DB) Phase: PlaceboDB Phase: NipocalimabOLE Phase: Nipocalimab (MOM-M281-004 and MOM-M281-005)Total
Female566610132
Male4232983
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Double Blind (DB) Phase: PlaceboDB Phase: NipocalimabOLE Phase: Nipocalimab (MOM-M281-004 and MOM-M281-005)Total
Hispanic or Latino610521
Not Hispanic or Latino898714190
Unknown or Not Reported3104
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Double Blind (DB) Phase: PlaceboDB Phase: NipocalimabOLE Phase: Nipocalimab (MOM-M281-004 and MOM-M281-005)Total
American Indian or Alaska Native0101
Asian2928057
Native Hawaiian or Other Pacific Islander0000
Black or African American1102
White656619150
More than one race0000
Unknown or Not Reported3205
08

Study locations

68 of 112 sites recruiting

Showing the first 100 of 112 sites across 17 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Claeys KG, Yang H, Gandhi K, Turkoz I, Fitzgibbon M, Pease S, Ramchandren S. Efficacy of nipocalimab in patients with moderate-to-severe ocular symptoms of generalized myasthenia gravis in the phase 3 Vivacity-MG3 study. Expert Opin Biol Ther. 2026 Aug 31. doi: 10.1080/14712598.2026.2725147. Online ahead of print. PubMed 42675831 ↗
  • Yu F, Myshkin E, Nguyen B, Bobadilla Mendez C, Cossu M, Fei K, Wang Q, Hubbard JJ, Campbell K, Ramchandren S, Rojo Cella R, Edwards R, Taylor PC, Gottenberg JE, Noaiseh G, Vu T, Antozzi C, Winthrop KL, Cuff CA, Loza MJ, Dimitrova D, Gao S. Effect of nipocalimab on IgG responses to vaccinations and viral infections in patients with IgG autoantibody-mediated diseases: Post hoc analyses of three randomized, placebo-controlled trials. Hum Vaccin Immunother. 2026 Dec;22(1):2664331. doi: 10.1080/21645515.2026.2664331. Epub 2026 May 5. PubMed 42084498 ↗
  • Antozzi C, Fitzgibbon M. An evaluation of nipocalimab for the treatment of generalized myasthenia gravis. Expert Opin Biol Ther. 2025 Oct;25(10):1047-1058. doi: 10.1080/14712598.2025.2561935. Epub 2025 Sep 30. PubMed 41021216 ↗
  • Raborn A, Savord A, Houts CR, Pease S, Scippa K, Ramchandren S. Psychometric analysis of the Neuro-QoL Fatigue in generalized Myasthenia Gravis (gMG) using data from a phase 3 trial. Qual Life Res. 2025 Sep;34(9):2577-2589. doi: 10.1007/s11136-025-03998-9. Epub 2025 Jun 14. PubMed 40515798 ↗
  • Antozzi C, Vu T, Ramchandren S, Nowak RJ, Farmakidis C, Bril V, De Bleecker J, Yang H, Minks E, Park JS, Grudniak M, Smilowski M, Sevilla T, Hoffmann S, Sivakumar K, Suzuki Y, Youssef E, Sanga P, Karcher K, Zhu Y, Sheehan JJ, Sun H; Vivacity-MG3 Study Group. Safety and efficacy of nipocalimab in adults with generalised myasthenia gravis (Vivacity-MG3): a phase 3, randomised, double-blind, placebo-controlled study. Lancet Neurol. 2025 Feb;24(2):105-116. doi: 10.1016/S1474-4422(24)00498-8. PubMed 39862879 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — The data sharing policy of Johnson \& Johnson Innovative Medicine is available at www.innovativemedicine.jnj.com/our-innovation/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu

Data sharing details ↗ · innovativemedicine.jnj.com

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2021 to primary completion in Nov 2023, 28 months.

Results were first posted in Jul 2025, 1 year 8 months after primary completion. A results delay was requested in Oct 2024.

Of 43 industry-sponsored phase 3 interventional studies under Myasthenia Gravis, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 39. This study's 28 months is close to that.

Counting every sponsor, half of 52 studies reached it within 30 months; a quarter within 20 and three quarters within 43.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 30, 2021
First posted
Jul 7, 2021
StartActual
Jul 15, 2021
Primary completionActual
Nov 17, 2023
CompletionEst.
Mar 29, 2029
Results delay requested
Oct 28, 2024
Results first posted
Jul 23, 2025
Last update
Nov 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
1 site added, 1 site removed
Show site
  • Teikyo University Hospital · tabashi City, Japan
Show 1 removed
  • Teikyo University Hospital · Itabashi Ku, Japan
Nov 5, 2026
Eligibility
1 exclusion criterion edited
What changed in the criteria
Exclusion criteria
  • EditedFor the SC Substudy (Cohort 1): Participants who have undergone a recent tapering of their concomitant MG medication in the OLE. Reminder that increasing the dose of existing MG therapy or starting new MG therapy anytime throughout study conduct is prohibited.
Nov 5, 2026
Publications
1 publication citing this study linked from PubMed, e.g. PubMed 42675831 ↗
Nov 5, 2026
Show all 1 update
  1. Nov 5, 2026
    Publications 1 publication citing this study linked from PubMed, e.g. PubMed 42675831 ↗
    1 site added, 1 site removed
    Show site
    • Teikyo University Hospital · tabashi City, Japan
    Show 1 removed
    • Teikyo University Hospital · Itabashi Ku, Japan
    Eligibility 1 exclusion criterion edited
    What changed in the criteria
    Exclusion criteria
    • EditedFor the SC Substudy (Cohort 1): Participants who have undergone a recent tapering of their concomitant MG medication in the OLE. Reminder that increasing the dose of existing MG therapy or starting new MG therapy anytime throughout study conduct is prohibited.
    + 2 other changes: identifiers and verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT04951622
Responsible party
Sponsor
First posted
Jul 7, 2021
Start date
Jul 15, 2021
Primary completion
Nov 17, 2023
Completion
Mar 29, 2029 (estimated)
Results posted
Jul 23, 2025
Last update
Nov 5, 2026

Study contacts

Study Contact
Contact
Participate-In-This-Study1@its.jnj.com
844-434-4210
Janssen Research & Development, LLC Clinical Trial
study director · Janssen Research & Development, LLC

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Nipocalimab

Start the discussion